Journal of Biological Chemistry · 2010 · 67 citations · 30 references
Life SciencesNeurosciencePharmacologyCellular NeuroscienceDrug DiscoveryStem Cell BiologyEmbryonic Stem CellsNeural Stem Cell BiologyNeural Stem CellsNeuronal Cell BiologyNeuronal DifferentiationNeurotransmissionAmpa Receptor FunctionAmpa ReceptorsEmbryonic Stem Cell BiologyGlutamate NeurotransmissionHigh-throughput Screening AssaysHuman Embryonic Stem CellsMouse Embryonic Stem CellsStem Cell-based Screening
Stem cell biology offers advantages to investigators seeking to identify new therapeutic molecules. Specifically, stem cells are genetically stable, scalable for molecular screening, and function in cellular assays for drug efficacy and safety. A key hurdle for drug discoverers of central nervous system disease is a lack of high quality neuronal cells. In the central nervous system, α-amino-3-hydroxyl-5-methyl-4-isoxazolepropionate (AMPA) subtype glutamate receptors mediate the vast majority of excitatory neurotransmissions. Embryonic stem (ES) cell protocols were developed to differentiate into neuronal subtypes that express AMPA receptors and were pharmacologically responsive to standard compounds for AMPA potentiation. Therefore, we hypothesized that stem cell-derived neurons should be predictive in high-throughput screens (HTSs). Here, we describe a murine ES cell-based HTS of a 2.4 × 106 compound library, the identification of novel chemical “hits” for AMPA potentiation, structure function relationship of compounds and receptors, and validation of chemical leads in secondary assays using human ES cell-derived neurons. This reporting of murine ES cell derivatives being formatted to deliver HTS of greater than 106 compounds for a specific drug target conclusively demonstrates a new application for stem cells in drug discovery. In the future new molecular entities may be screened directly in human ES or induced pluripotent stem cell derivatives. Stem cell biology offers advantages to investigators seeking to identify new therapeutic molecules. Specifically, stem cells are genetically stable, scalable for molecular screening, and function in cellular assays for drug efficacy and safety. A key hurdle for drug discoverers of central nervous system disease is a lack of high quality neuronal cells. In the central nervous system, α-amino-3-hydroxyl-5-methyl-4-isoxazolepropionate (AMPA) subtype glutamate receptors mediate the vast majority of excitatory neurotransmissions. Embryonic stem (ES) cell protocols were developed to differentiate into neuronal subtypes that express AMPA receptors and were pharmacologically responsive to standard compounds for AMPA potentiation. Therefore, we hypothesized that stem cell-derived neurons should be predictive in high-throughput screens (HTSs). Here, we describe a murine ES cell-based HTS of a 2.4 × 106 compound library, the identification of novel chemical “hits” for AMPA potentiation, structure function relationship of compounds and receptors, and validation of chemical leads in secondary assays using human ES cell-derived neurons. This reporting of murine ES cell derivatives being formatted to deliver HTS of greater than 106 compounds for a specific drug target conclusively demonstrates a new application for stem cells in drug discovery. In the future new molecular entities may be screened directly in human ES or induced pluripotent stem cell derivatives. IntroductionCognitive impairment is a fundamental trademark of many CNS 2The abbreviations used are: CNScentral nervous systemAMPAα-amino-3-hydroxyl-5-methyl-4-isoxazolepropionateHTShigh-throughput screen(ing)ESembryonic stemmESmouse ESiPSinduced pluripotent stemFLiPRfluorimetric imaging plate readerCTZcyclothiazideDMEMDulbecco's modified Eagle's mediumEBembryoid bodyKSRknock-out serum replacementGABAergicaminobutyric acid-ergicFGFfibroblast growth factorPBSphosphate-buffered salineTHtyrosine hydroxylaseGFAPglial fibrillary acidic proteinChATcholinesterol acelyltransferaseGABAγ-aminobutyric acid. diseases such as Alzheimer disease, schizophrenia, and attention deficit hyperactivity disorder. Unfortunately few pharmaceutical agents have proven to be efficacious in treating cognitive impairment. As such, the medical need for new therapeutic approaches for improving cognitive deficits has emerged as an important frontier in treating central nervous system diseases. Glutamate mediates the vast majority of excitatory neurotransmission in the CNS with post-synaptic signaling regulated by either ligand-gated cation channels (ionotropic) or G-protein-coupled receptors (metabotropic). Ionotropic α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors are tetrameric aggregates composed of combinations of one or more of four subunits (GluR1–4) that can each bind a glutamate neurotransmitter molecule. Upon binding of glutamate, the associated ion channel pore opens, allowing cations to cross the membrane and depolarize the postsynaptic cell. Termination of the postsynaptic signal is driven primarily by the removal of glutamate from the synaptic cleft, reducing the occupancy of the glutamate binding site and subsequent channel closure (deactivation). Additionally, the conduction pathway will close in the continued presence of bound agonist as a result of conformational changes secondary to glutamate binding (desensitization).AMPA receptor pharmacology has identified agonists, competitive and non-competitive antagonists, and positive allosteric modulators (3Kew J.N. Kemp J.A. Psychopharmacology. 2005; 179: 4-29Crossref PubMed Scopus (582) Google Scholar). This latter class of pharmacologic agent, the positive allosteric modulator or AMPA potentiator, enhances agonist-evoked currents by slowing deactivation and/or desensitization but does not evoke a response when applied in the absence of agonist. These AMPA-potentiators demonstrate modulation of the excitatory post-synaptic currents in vitro and in vivo and are efficacious in animal cognition models such as novel object recognition (4Silvers J.M. Harrod S.B. Mactutus C.F. Booze R.M. J. Neurosci. Methods. 2007; 166: 99-103Crossref PubMed Scopus (80) Google Scholar) and radial arm maze (5Olton D.S. Physiol. Behav. 1987; 40: 793-797Crossref PubMed Scopus (183) Google Scholar, 6Levin E.D. Neurosci. Biobehav. Rev. 1988; 12: 169-175Crossref PubMed Scopus (108) Google Scholar). AMPA potentiators are believed to increase cognition by enhancing synaptic transmission and plasticity and by stimulating release of neurotrophins (7Lynch G. Curr. Opin. Pharmacol. 2006; 6: 82-88Crossref PubMed Scopus (137) Google Scholar).The nootropic agents such as aniracetam and piracetam have been used clinically to treat cognitive impairment and have also been shown to enhance AMPA receptor function. However, the marginal efficacy of these first generation compounds has led to interest in developing agents that are more potent and selective enhancers of AMPA receptor function. Although several novel AMPA receptor potentiators meeting these criteria have advanced to clinical testing, none is yet approved, and there remains opportunity for new molecules of this general class (8Lynch G. Curr. Opin. Pharmacol. 2004; 4: 4-11Crossref PubMed Scopus (114) Google Scholar, 9Black M.D. Psychopharmacology. 2005; 179: 154-163Crossref PubMed Scopus (152) Google Scholar, 10Francotte P. de Tullio P. Fraikin P. Counerotte S. Goffin E. Pirotte B. Recent Pat. CNS Drug Discov. 2006; 1: 239-246Crossref PubMed Scopus (28) Google Scholar, 11O'Neill M.J. Dix S. IDrugs. 2007; 10: 185-192PubMed Google Scholar).Typically primary, transformed, or genetically engineered cell lines are used for developing cell-based assays in drug discovery. Stem cells offer distinct advantages because of their ability to differentiate into genetically and functionally normal cells (12McNeish J. Nat. Rev. Drug Discov. 2004; 3: 70-80Crossref PubMed Scopus (160) Google Scholar). For AMPA receptors, this is particularly relevant due to the multitude of distinct AMPA receptor subtypes formed as mixtures of four subunits, each having flip and flop splice isoforms. Adding to this complexity are striking GluR subunit editing by double-stranded RNA, developmentally regulated alternative splicing, and transmembrane AMPA receptor regulatory proteins (TARPs) that modulate desensitization and pharmacology (1Schoft V.K. Schopoff S. Jantsch M.F. Nucleic Acids Res. 2007; 35: 3723-3732Crossref PubMed Scopus (70) Google Scholar, 2Kato A.S. Siuda E.R. Nisenbaum E.S. Bredt D.S. Neuron. 2008; 59: 986-996Abstract Full Text Full Text PDF PubMed Scopus (97) Google Scholar).From the perspective of developing a novel therapeutic agent, it is not clear that any one or more combinations of subunits and associated proteins is more or less desirable than the others. Therefore, mouse embryonic stem (mES) cells were differentiated into neuronal precursor cells that consistently expressed functional AMPA receptors. It was speculated that this approach would offer the potential to interrogate an array of AMPA receptors comprising different and possibly naturally occurring subunit combinations with the goal of casting a broad net in the HTS.Herein we report the development and application of an mES cell-derived neuronal HTS that was used to assay more than 2.4 million small molecules. From this effort, small drug-like molecules were discovered and subjected to further evaluation to assess their functional and binding properties. In addition, selected molecules were tested in human ES cell-derived neurons to assess translation from mouse to human receptors. To our knowledge this is the first report of any stem cell-based HTS being employed to identify biologically active lead molecules for a pharmacologically relevant target. Importantly, this approach can potentially be used for other central nervous system drug targets that are not easily reconstituted using traditional expression systems.DISCUSSIONThe overriding goal of drug discovery is to rapidly identify novel compounds with the potential for superior clinical efficacy and safety. Typically, in vitro and in vivo models are identified and optimized to ensure that targets are validated, lead molecules are rapidly identified, and potential candidates are selected for characterization in human clinical trials. Stem cells have a more innate cellular background than typical exogenous expression systems that may provide a more predictive cell-based screening strategy for small molecule lead identification. Herein, we have described a mouse ES cell-based approach to primary screening that resulted in the identification of novel small molecule AMPA-type glutamate receptor potentiators. Although AMPA potentiators are of interest in enhancing cognition for several CNS disorders, this stem cell-based screening strategy could be used in the identification of substrates for other CNS targets. Currently, artificially engineered cells or primary cells from fetal rat brains are used for CNS assays, and although many successful cell-based HTS have been developed, many have not been optimal. In the case of G-protein-coupled receptors, for instance, a number of important variables may exist with these systems including stoichiometry of the target receptors versus the endogenous cell populations and proper signaling within the engineered cells. The mES cell-derived neurons provide a novel alternative for identifying AMPA potentiators that exploits endogenously expressed glutamate receptors that potentially represent the range and stoichiometry of subunit combinations and splice isoforms. The HTS identified two novel chemical structures with positive AMPA activity that were confirmed in secondary assays and in human ES cell-derived neuron FLiPR assay. Further evaluation of these newly identified structures and related analogs as leads in the development of new therapies for cognition enhancement continues and will be reported in due course.One concern of stem cell based screen was that the cells would express multiple receptors and signaling pathways that could elicit a Ca2+ signal in the FLiPR assay. This could produce an unmanageable number of false positives in a single addition assay. However, the criteria used for selecting compounds that were inactive when added alone, but demonstrated enhanced Ca2+ flux when evoked by AMPA, appeared to eliminate the vast majority of compounds that acted as either direct agonist of AMPA receptors or on receptors that also couple to Ca2+. Therefore, stem cell-based screening assays are likely to be useful for target mechanisms that can be isolated from other systems in the stem cell derivatives, such as the case of allosteric modulators. Advances in automation and miniaturization have resulted in HTS of chemical libraries, often exceeding a million individual molecules, and is the major lead-generating technology employed in the pharmaceutical industry. In this work we coupled the advantages of stem cell biology and HTS to identify new lead molecules in an important area of unmet medical need. Specifically, a murine embryonic stem cell-derived assay has been developed to screen a compound file containing more than two million compounds. Particularly noteworthy is the fact that heretofore no stem cell-based assay has been employed in a HTS on the order of 106 compounds or more. The work described here was accomplished using mouse ES cells; however, recent advances suggest that hES cell-derived neurons can be reproducibly scaled and quality-controlled during differentiation to consider moving directly to primary HTS in human cells (26Shin S. Mitalipova M. Noggle S. Tibbitts D. Venable A. Rao R. Stice S.L. Stem Cells. 2006; 24: 125-138Crossref PubMed Scopus (159) Google Scholar). If possible, this may eliminate translational differences between murine and human cellular generated data, as was observed in this study where 4/21 hits showed a 10× affinity difference between mouse and human cells. Recently, investigators have reported moving directly to human ES cells to enable phenotypic screening of thousands of compounds (36Desbordes S.C. Placantonakis D.G. Ciro A. Socci N.D. Lee G. Djaballah H. Studer L. Cell Stem Cell. 2008; 2: 602-612Abstract Full Text Full Text PDF PubMed Scopus (193) Google Scholar, 37Borowiak M. Maehr R. Chen S. Chen A.E. Tang W. Fox J.L. Schreiber S.L. Melton D.A. Cell Stem Cell. 2009; 4: 348-358Abstract Full Text Full Text PDF PubMed Scopus (344) Google Scholar, 38Chen S. Borowiak M. Fox J.L. Maehr R. Osafune K. Davidow L. Lam K. Peng L.F. Schreiber S.L. Rubin L.L. Melton D. Nat. Chem. Biol. 2009; 5: 258-265Crossref PubMed Scopus (411) Google Scholar).In addition, researchers have demonstrated the ability to reprogram somatic cells that have properties similar to embryonic cells. These induced pluripotent stem (iPS) cells were first described in murine cells (39Takahashi K. Yamanaka S. Cell. 2006; 126: 663-676Abstract Full Text Full Text PDF PubMed Scopus (18472) Google Scholar) and were followed by the derivation of human iPS cell lines (40Takahashi K. Tanabe K. Ohnuki M. Narita M. Ichisaka T. Tomoda K. Yamanaka S. Cell. 2007; 131: 861-872Abstract Full Text Full Text PDF PubMed Scopus (14654) Google Scholar, 41Yu J. Vodyanik M.A. Smuga-Otto K. Antosiewicz-Bourget J. Frane J.L. Tian S. Nie J. Jonsdottir G.A. Ruotti V. Stewart R. Slukvin I.I. Thomson J.A. Science. 2007; 318: 1917-1920Crossref PubMed Scopus (8045) Google Scholar). Human iPS cells have been achieved for known genetic diseases (42Park I.H. Arora N. Huo H. Maherali N. Ahfeldt T. Shimamura A. Lensch M.W. Cowan C. Hochedlinger K. Daley G.Q. Cell. 2008; 134: 877-886Abstract Full Text Full Text PDF PubMed Scopus (1790) Google Scholar). Like ES cells, iPS cells have been differentiated into clinically relevant cells types including neurons (43Chambers S.M. Fasano C.A. Papapetrou E.P. Tomishima M. Sadelain M. Studer L. Nat. Biotechnol. 2009; 27: 275-280Crossref PubMed Scopus (2346) Google Scholar), cardiomyocytes (44Zhang J. Wilson G.F. Soerens A.G. Koonce C.H. Yu J. Palecek S.P. Thomson J.A. Kamp T.J. Circ. Res. 2009; 104: e30-e41Crossref PubMed Scopus (1069) Google Scholar), hepatocytes (45Song Z. Cai J. Liu Y. Zhao D. Yong J. Duo S. Song X. Guo Y. Zhao Y. Qin H. Yin X. Wu C. Che J. Lu S. Ding M. Deng H. Cell Res. 2009; 19: 1233-1242Crossref PubMed Scopus (408) Google Scholar), and insulin-producing cells (46Zhang D. Jiang W. Liu M. Sui X. Yin X. Chen S. Shi Y. Deng H. Cell Res. 2009; 19: 429-438Crossref PubMed Scopus (460) Google Scholar). Accordingly, iPS cells may soon deliver a range of disease specific stem cells for primary HTS and secondary screening of validated targets.In summary, this report demonstrates a breakthrough in drug discovery technology that applies stem cell biology with high throughput screening of very large chemical collections or libraries. It is expected that stem cells will have an expanded role in future HTS in the biopharmaceutical industry. Also, we predict that in the near future the extension of the work described here will be applied to human ES/iPS stem cells leading to further efficiencies in drug discovery and the delivery of safer and effective new medicines. IntroductionCognitive impairment is a fundamental trademark of many CNS 2The abbreviations used are: CNScentral nervous systemAMPAα-amino-3-hydroxyl-5-methyl-4-isoxazolepropionateHTShigh-throughput screen(ing)ESembryonic stemmESmouse ESiPSinduced pluripotent stemFLiPRfluorimetric imaging plate readerCTZcyclothiazideDMEMDulbecco's modified Eagle's mediumEBembryoid bodyKSRknock-out serum replacementGABAergicaminobutyric acid-ergicFGFfibroblast growth factorPBSphosphate-buffered salineTHtyrosine hydroxylaseGFAPglial fibrillary acidic proteinChATcholinesterol acelyltransferaseGABAγ-aminobutyric acid. diseases such as Alzheimer disease, schizophrenia, and attention deficit hyperactivity disorder. Unfortunately few pharmaceutical agents have proven to be efficacious in treating cognitive impairment. As such, the medical need for new therapeutic approaches for improving cognitive deficits has emerged as an important frontier in treating central nervous system diseases. Glutamate mediates the vast majority of excitatory neurotransmission in the CNS with post-synaptic signaling regulated by either ligand-gated cation channels (ionotropic) or G-protein-coupled receptors (metabotropic). Ionotropic α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors are tetrameric aggregates composed of combinations of one or more of four subunits (GluR1–4) that can each bind a glutamate neurotransmitter molecule. Upon binding of glutamate, the associated ion channel pore opens, allowing cations to cross the membrane and depolarize the postsynaptic cell. Termination of the postsynaptic signal is driven primarily by the removal of glutamate from the synaptic cleft, reducing the occupancy of the glutamate binding site and subsequent channel closure (deactivation). Additionally, the conduction pathway will close in the continued presence of bound agonist as a result of conformational changes secondary to glutamate binding (desensitization).AMPA receptor pharmacology has identified agonists, competitive and non-competitive antagonists, and positive allosteric modulators (3Kew J.N. Kemp J.A. Psychopharmacology. 2005; 179: 4-29Crossref PubMed Scopus (582) Google Scholar). This latter class of pharmacologic agent, the positive allosteric modulator or AMPA potentiator, enhances agonist-evoked currents by slowing deactivation and/or desensitization but does not evoke a response when applied in the absence of agonist. These AMPA-potentiators demonstrate modulation of the excitatory post-synaptic currents in vitro and in vivo and are efficacious in animal cognition models such as novel object recognition (4Silvers J.M. Harrod S.B. Mactutus C.F. Booze R.M. J. Neurosci. Methods. 2007; 166: 99-103Crossref PubMed Scopus (80) Google Scholar) and radial arm maze (5Olton D.S. Physiol. Behav. 1987; 40: 793-797Crossref PubMed Scopus (183) Google Scholar, 6Levin E.D. Neurosci. Biobehav. Rev. 1988; 12: 169-175Crossref PubMed Scopus (108) Google Scholar). AMPA potentiators are believed to increase cognition by enhancing synaptic transmission and plasticity and by stimulating release of neurotrophins (7Lynch G. Curr. Opin. Pharmacol. 2006; 6: 82-88Crossref PubMed Scopus (137) Google Scholar).The nootropic agents such as aniracetam and piracetam have been used clinically to treat cognitive impairment and have also been shown to enhance AMPA receptor function. However, the marginal efficacy of these first generation compounds has led to interest in developing agents that are more potent and selective enhancers of AMPA receptor function. Although several novel AMPA receptor potentiators meeting these criteria have advanced to clinical testing, none is yet approved, and there remains opportunity for new molecules of this general class (8Lynch G. Curr. Opin. Pharmacol. 2004; 4: 4-11Crossref PubMed Scopus (114) Google Scholar, 9Black M.D. Psychopharmacology. 2005; 179: 154-163Crossref PubMed Scopus (152) Google Scholar, 10Francotte P. de Tullio P. Fraikin P. Counerotte S. Goffin E. Pirotte B. Recent Pat. CNS Drug Discov. 2006; 1: 239-246Crossref PubMed Scopus (28) Google Scholar, 11O'Neill M.J. Dix S. IDrugs. 2007; 10: 185-192PubMed Google Scholar).Typically primary, transformed, or genetically engineered cell lines are used for developing cell-based assays in drug discovery. Stem cells offer distinct advantages because of their ability to differentiate into genetically and functionally normal cells (12McNeish J. Nat. Rev. Drug Discov. 2004; 3: 70-80Crossref PubMed Scopus (160) Google Scholar). For AMPA receptors, this is particularly relevant due to the multitude of distinct AMPA receptor subtypes formed as mixtures of four subunits, each having flip and flop splice isoforms. Adding to this complexity are striking GluR subunit editing by double-stranded RNA, developmentally regulated alternative splicing, and transmembrane AMPA receptor regulatory proteins (TARPs) that modulate desensitization and pharmacology (1Schoft V.K. Schopoff S. Jantsch M.F. Nucleic Acids Res. 2007; 35: 3723-3732Crossref PubMed Scopus (70) Google Scholar, 2Kato A.S. Siuda E.R. Nisenbaum E.S. Bredt D.S. Neuron. 2008; 59: 986-996Abstract Full Text Full Text PDF PubMed Scopus (97) Google Scholar).From the perspective of developing a novel therapeutic agent, it is not clear that any one or more combinations of subunits and associated proteins is more or less desirable than the others. Therefore, mouse embryonic stem (mES) cells were differentiated into neuronal precursor cells that consistently expressed functional AMPA receptors. It was speculated that this approach would offer the potential to interrogate an array of AMPA receptors comprising different and possibly naturally occurring subunit combinations with the goal of casting a broad net in the HTS.Herein we report the development and application of an mES cell-derived neuronal HTS that was used to assay more than 2.4 million small molecules. From this effort, small drug-like molecules were discovered and subjected to further evaluation to assess their functional and binding properties. In addition, selected molecules were tested in human ES cell-derived neurons to assess translation from mouse to human receptors. To our knowledge this is the first report of any stem cell-based HTS being employed to identify biologically active lead molecules for a pharmacologically relevant target. Importantly, this approach can potentially be used for other central nervous system drug targets that are not easily reconstituted using traditional expression systems.
30
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Kazutoshi Takahashi, Koji Tanabe, Mari Ohnuki et al. · Cell · 2007 · 20.2K citations
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Junying Yu, Maxim A. Vodyanik, Kim Smuga-Otto et al. · Science · 2007 · 10.3K citations
Disease-Specific Induced Pluripotent Stem Cells
In‐Hyun Park, Natasha Arora, Hongguang Huo et al. · Cell · 2008 · 2.2K citations · Full text